bioAffinity Technologies Sees Accelerating Growth Of Physician Practices Ordering CyPath Lung Tests
Portfolio Pulse from Benzinga Newsdesk
bioAffinity Technologies, Inc. (NASDAQ:BIAF) reported a 139% growth in the number of pulmonology practices and physicians offering its CyPath® Lung test since January 1, 2024. The company is ahead of forecasts in onboarding pathology practices.
June 12, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
bioAffinity Technologies reported significant growth in the adoption of its CyPath® Lung test, with a 139% increase in the number of pulmonology practices and physicians offering the test since January 1, 2024. The company is also ahead of forecasts in onboarding pathology practices.
The significant growth in the number of practices offering CyPath® Lung and the company being ahead of forecasts in onboarding pathology practices indicate strong market acceptance and potential revenue growth. This is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100